Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis

  • Taking Part in OPTIMA
  • OPTIMA Recruiting Sites
  • The OPTIMA Team
  • Contact Us
  • Taking Part in OPTIMA
    • COVID-19 and OPTIMA
    • About treatment for breast cancer
    • About OPTIMA
    • Who can take part?
    • What's involved in taking part?
    • Patient and public engagement (PPI)
    • More information
    • Is my local hospital recruiting?
    • Privacy Statement
  • OPTIMA Sites
    • COVID-19 and OPTIMA
    • Essential dcuments
    • Newsletters
    • Administering OPTIMA
    • Qualitative Recruitment Study
    • Recruiter training and support
    • Publications
    • OPTIMA governance
  • The OPTIMA Team
  • Contact Us

  • Essential Documents
  • Newsletters
  • Administering OPTIMA
  • Qualitative Recruitment Study
  • Recruiter training and support
  • Publications
  • OPTIMA Governance

OPTIMA Investigator Meeting

Royal Institution, London

25 April 2023

Capture

Slides

  • Stein, R - RI Investigator Meeting Welcome
  • Dotchin, G - Progress in OPTIMA
  • Stein, R - Completing OPTIMA - International Collaboration & more
  • MacPherson, I - Genomic Assays
  • Hughes-Davies, L - Abemaciclib
  • King, J - Endocrine therapy for pre-menopausal women
  • Guppy, A - Endocrine therapy for post
  • Marcom, K - Intrinsic Subtypes: Biologic and Clinical Data
  • Fleming, L - Insomnia in breast cancer
  • Coleman, R - Adjuvant Bisphosphonates

© 2019 OPTIMA

ABS Badge The OPTIMA Study is funded by National Institute for Health Research (NIHR), Programme (project reference 10/34/501). The information contained in this website is for general information about the OPTIMA study and is provided by the University of Warwick Clinical Trials Unit & University College London. The views expressed are those of the author(s) and are not necessarily those of NIHR or the Department of Health and Social Care or representative of the views of the funder, sponsor or other participating organisations. Trial Registration Number ISRCTN42400492